AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|AAPL325.28+9.94 (+3.15%) ▲|ABBV253.57+2.66 (+1.06%) ▲|ABT103.82-1.42 (-1.34%) ▼|ACN177.64+1.84 (+1.05%) ▲|ADBE249.37-5.49 (-2.15%) ▼|AMAT457.63-11.22 (-2.39%) ▼|AMD506.42-14.68 (-2.82%) ▼|AMGN382.73-8.54 (-2.18%) ▼|AMT172.86-2.57 (-1.47%) ▼|AMZN252.26-0.15 (-0.06%) ▼|AVGO362.82-1.56 (-0.43%) ▼|AXP320.69-1.12 (-0.35%) ▼|BA206.24-0.18 (-0.09%) ▼|BAC62.40-0.28 (-0.44%) ▼|BKNG175.74+2.31 (+1.33%) ▲|BLK1,069.35-2.69 (-0.25%) ▼|BMY63.95-0.46 (-0.71%) ▼|BNY162.29-0.22 (-0.14%) ▼|BRK-B504.93-1.79 (-0.35%) ▼|C137.99+0.19 (+0.14%) ▲|CAT802.09-13.48 (-1.65%) ▼|CL88.23+0.20 (+0.23%) ▲|CMCSA25.15+0.56 (+2.26%) ▲|COF207.55-3.31 (-1.57%) ▼|COP137.88+1.35 (+0.99%) ▲|COST899.44-3.16 (-0.35%) ▼|CRM244.04-0.12 (-0.05%) ▼|CSCO108.19-1.24 (-1.13%) ▼|CVS95.24-0.14 (-0.15%) ▼|CVX213.52-0.30 (-0.14%) ▼|DE674.07-3.14 (-0.46%) ▼|DHR201.69-3.17 (-1.55%) ▼|DIS104.89+0.71 (+0.68%) ▲|DUK119.64-0.80 (-0.66%) ▼|EMR147.52-2.83 (-1.88%) ▼|FDX311.06+1.87 (+0.60%) ▲|GD353.48+0.81 (+0.23%) ▲|GE322.87-2.55 (-0.78%) ▼|GEV925.75-25.29 (-2.66%) ▼|GILD145.05-0.60 (-0.41%) ▼|GM85.49+1.73 (+2.07%) ▲|GOOG329.31+0.93 (+0.28%) ▲|GOOGL331.57+0.92 (+0.28%) ▲|GS1,020.01-8.77 (-0.85%) ▼|HD305.21-5.24 (-1.69%) ▼|HON202.18-2.76 (-1.34%) ▼|IBM236.33-3.62 (-1.51%) ▼|INTC101.37-4.87 (-4.58%) ▼|INTU312.62-1.32 (-0.42%) ▼|ISRG360.15+6.91 (+1.96%) ▲|JNJ266.75-0.34 (-0.13%) ▼|JPM352.80-1.91 (-0.54%) ▼|KO88.14+0.59 (+0.67%) ▲|LIN461.61-5.05 (-1.08%) ▼|LLY1,126.61+2.40 (+0.21%) ▲|LMT528.21+3.75 (+0.72%) ▲|LOW195.79-2.82 (-1.42%) ▼|LRCX300.79-15.05 (-4.77%) ▼|MA564.19-3.32 (-0.58%) ▼|MCD253.70+0.22 (+0.08%) ▲|MDLZ62.26-0.16 (-0.26%) ▼|MDT91.36-0.53 (-0.58%) ▼|META649.75-3.94 (-0.60%) ▼|MMM162.34-2.06 (-1.25%) ▼|MO68.67+0.78 (+1.14%) ▲|MRK145.04-2.50 (-1.69%) ▼|MS213.84-1.51 (-0.70%) ▼|MSFT492.38+0.73 (+0.15%) ▲|MU979.91-47.87 (-4.66%) ▼|NEE82.55-0.10 (-0.12%) ▼|NFLX75.99-0.05 (-0.06%) ▼|NKE36.81-0.54 (-1.45%) ▼|NOW131.94+0.83 (+0.63%) ▲|NVDA218.46-5.21 (-2.33%) ▼|ORCL156.58-5.05 (-3.12%) ▼|PEP136.89+0.20 (+0.15%) ▲|PFE27.51-0.28 (-0.99%) ▼|PG142.91+0.27 (+0.19%) ▲|PLTR166.14-3.39 (-2.00%) ▼|PM189.15+3.44 (+1.85%) ▲|QCOM180.12+3.72 (+2.11%) ▲|RTX197.41-0.14 (-0.07%) ▼|SBUX99.65-0.39 (-0.39%) ▼|SCHW106.74+0.20 (+0.18%) ▲|SO87.91-0.44 (-0.49%) ▼|SPG205.94+1.41 (+0.69%) ▲|T25.53+0.38 (+1.49%) ▲|TMO603.01-2.68 (-0.44%) ▼|TMUS175.87-1.47 (-0.83%) ▼|TSLA366.60-1.21 (-0.33%) ▼|TXN259.47-2.12 (-0.81%) ▼|UBER72.45+1.37 (+1.93%) ▲|UNH390.92-2.14 (-0.54%) ▼|UNP284.23-0.52 (-0.18%) ▼|UPS100.08+0.86 (+0.86%) ▲|USB62.01-0.11 (-0.17%) ▼|V366.59-0.80 (-0.22%) ▼|VZ49.92+0.18 (+0.36%) ▲|WFC88.94-0.74 (-0.82%) ▼|WMT105.89+0.06 (+0.05%) ▲|XOM165.42+1.19 (+0.72%) ▲|
30.6 C
New York
Thursday, September 10, 2026

Tag: patient

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

Biosurgery Market worth US$21.59 Billion by 2030 with 6.4% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., July 28, 2025 /PRNewswire/ -- The global Biosurgery Market, valued at US$14.96 billion in 2024 stood at US$15.83 billion in 2025 and...

NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025

SANTA ANA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced the presentation of a poster entitled, “Mechanism of Action of Troculeucel (Non-genetically Modified Natural Killer Cells with Enhanced Cytotoxicity) in Alzheimer's Disease Confirmed by Corresponding Phase I Biomarker Data” at the Alzheimer’s Association International Conference 2025 (“AAIC 2025”) held in Toronto, Canada and online from July 27-31, 2025.

Interventional Robot’s RCT Research Published in JNIS, a Leading Journal in Neurointervention!

SHANGHAI, July 28, 2025 /PRNewswire/ -- The multicenter, randomized controlled trial (RCT) results of the PANVIS-A® NeuroInterventional Robotic System—led by Professor Liu Jianmin (Changhai Hospital)...

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

CELEBRATION, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare diseases, announced the company submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). NPC is an ultra-rare, neurological disease caused by genetic mutations that result in lipid accumulation in cells, leading to visceral, neurological, and psychiatric symptoms. Arimoclomol is the only treatment shown to directly target the underlying pathology of NPC by increasing gene expression for improved lipid clearance. Arimoclomol for the treatment of NPC has been designated as an Orphan Medicinal Product by the EMA. Arimoclomol is marketed in the U.S. under the brand name MIPLYFFA®.

Elevate Your Portfolio: Top 3 Dow Stocks Women Should Watch for 2025 Success

Hey, fabulous financial friends! 🚀 Ready to shake up your investment strategy? Let's dive into why it might be time to swap those risky...

Roche presents new insights in Alzheimer’s disease research across its diagnostics and pharmaceutical portfolios at AAIC

Basel, 28 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its Alzheimer’s development portfolio is being presented at the Alzheimer’s Association International Conference (AAIC) in Toronto, Canada (July 27-30). These data exemplify the comprehensive approach Roche is taking in addressing Alzheimer’s across the entire patient journey. 

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

SHANGHAI and HONG KONG, July 28, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Antengene Announces Poster Presentation of ATG-022 (Claudin 18.2 ADC) at ESMO 2025

SHANGHAI and HONG KONG, July 27, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action...

Hims & Hers Health, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud class action deadline.

REPL CLASS ACTION ALERT: FDA Response Letter Leads to Replimune Group, Inc. Class Action – Investors are Notified to Contact BFA Law by September...

Replimune Group, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Caribou (CRBU) To Contact Him Directly To Discuss Their Options

Nutex Health (NUTX) Shares Fall Amid Critical Blue Orca Report — Hagens Berman

SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- On July 22, 2025, investors in Nutex Health Inc. (NASDAQ: NUTX) saw the price of their shares significantly fall after activist investment firm Blue Orca Capital published a critical report about Nutex and its involvement with independent dispute resolution (“IDR”) vendor HaloMD.

PharmAla Issues Q3 Financial Statements

PharmAla releases Q3 financials showing increased customer deposit and SAP sales growth

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPatient